AN OVERVIEW OF ALZHEIMER'S DISEASE THERAPIES AND THEIR CLINICAL LIMITATIONS
Fuente:
Zenodo
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866902112536887296 |
|---|---|
| author | Rasulova, Vasila Saidov, Saidamir |
| author_facet | Rasulova, Vasila Saidov, Saidamir |
| contents | <p><span lang="EN-US"><span> </span>Neurodegenerative diseases (NDs) represent a growing global health challenge, driven by an aging population, modern lifestyle factors, increasing prevalence, and the substantial physical, emotional, and financial burdens placed on patients, caregivers, and healthcare systems. Currently, over 50 million individuals worldwide are affected by NDs, and this figure is projected to nearly triple to 152 million by 2050 if no effective preventive or therapeutic measures are developed. Among these disorders, Alzheimer’s disease (AD) is the most prevalent, accounting for approximately 60% to 80% of all neurodegenerative cases.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15221140 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | AN OVERVIEW OF ALZHEIMER'S DISEASE THERAPIES AND THEIR CLINICAL LIMITATIONS Rasulova, Vasila Saidov, Saidamir <p><span lang="EN-US"><span> </span>Neurodegenerative diseases (NDs) represent a growing global health challenge, driven by an aging population, modern lifestyle factors, increasing prevalence, and the substantial physical, emotional, and financial burdens placed on patients, caregivers, and healthcare systems. Currently, over 50 million individuals worldwide are affected by NDs, and this figure is projected to nearly triple to 152 million by 2050 if no effective preventive or therapeutic measures are developed. Among these disorders, Alzheimer’s disease (AD) is the most prevalent, accounting for approximately 60% to 80% of all neurodegenerative cases.</span></p> |
| title | AN OVERVIEW OF ALZHEIMER'S DISEASE THERAPIES AND THEIR CLINICAL LIMITATIONS |
| url | https://doi.org/10.5281/zenodo.15221140 |